#1123
Real world treatment outcomes for metastatic urothelial carcinoma
Y. LAI1, G. LAI1, J. LI1, C. YANG1, S. WANG1
1Taichung Veterans General Hospital, Urology, Taichung, Taiwan
Introduction:
Metastatic urothelial carcinoma (mUC) is an aggressive malignancy with a poor prognosis. Current treatment guidelines recommend chemotherapy as the first-line therapy for eligible patients, but immune checkpoint inhibitors and antibody-drug conjugates have shown promising results. Enfortumab vedotin and pembrolizumab (EV+P) is a novel combination therapy demonstrating significant efficacy in clinical trials compared to standard chemotherapy. TriNetX, a global health research network, enables real-world evidence generation through large-scale, de-identified patient data.
Material and methods:
This study utilized the TriNetX platform to perform a retrospective analysis comparing two cohorts of patients diagnosed with mUC. Cohort 1 included patients receiving EV+P, while Cohort 2 included those treated with cisplatin-based chemotherapy. Kaplan-Meier analysis was used to evaluate overall survival (OS) between the two groups, and propensity score matching was performed to minimize selection bias.
Results:
After matching, 485 patients were included in each cohort. The Kaplan-Meier analysis revealed a statistically significant improvement in OS for the EV+P group compared to the chemotherapy group. The median survival days in EV+P group is 771 days, and 517 days in chemotherapy group with a p-value of 0.0035.